Metaplastic breast cancer: A review

被引：33

作者：

Thomas, Horatio R. ^{[1
,5
]}

Hu, Bonnie ^{[2
,6
]}

Boyraz, Baris ^{[3
,7
]}

Johnson, Andrew ^{[2
,8
]}

Bossuyt, Veerle I. ^{[3
,9
]}

Spring, Laura ^{[4
,10
]}

Jimenez, Rachel B. ^{[11
]}

机构：

[1] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94118 USA

[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA

[3] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[4] Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA USA

[5] UC San Francisco, Dept Radiat Oncol, Boston, MA USA

[6] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA

[7] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[8] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA

[9] Massachusetts Gen Hosp, Dept Pathol, Div Breast Pathol, Boston, MA USA

[10] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA USA

[11] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 182卷

关键词：

Metaplastic breast cancer; Pathology; Epithelial-to-mesenchymal transition; Clinical management; Targeted therapy; Immunotherapy; Clinical outcomes; INVASIVE DUCTAL CARCINOMA; CLINICOPATHOLOGICAL FEATURES; MESENCHYMAL TRANSITION; PD-L1; EXPRESSION; REVEALS FREQUENT; OUTCOMES; PROGNOSIS; MANAGEMENT; RESISTANCE; PATTERNS;

D O I：

10.1016/j.critrevonc.2023.103924

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metaplastic breast cancer (MpBC) is an uncommon aggressive malignancy that is associated with a poor prognosis. Due to its rarity, the relationships between the clinical and pathological features of MpBC, treatment approach, and clinical outcomes remain underexplored. In the following review article, we synthesize the existing data on the clinical, pathological and genomic features, management, and outcomes of MpBC. We also identify potential targets for future clinical trials.

引用

页数：11

共 86 条

[1]

Abada E, 2022, ARCH PATHOL LAB MED, V146, P341, DOI [10.5858/arpa.2020-0830.OA, 10.5858/arpa.2020-0830-OA]

[2] Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors [J].

Abraham Barquet-Munoz, Salim ;

Patricia Villarreal-Colin, Silvia ;

Alonso Herrera-Montalvo, Luis ;

Soto-Reyes, Ernesto ;

Perez-Plasencia, Carlos ;

Coronel-Martinez, Jaime ;

Perez-Montiel, Delia ;

Vazquez-Romo, Rafael ;

Cantu de Leon, David .

BMC CANCER, 2015, 15

[3] A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609) [J].

Adams, Sylvia ;

Othus, Megan ;

Patel, Sandip Pravin ;

Miller, Kathy D. ;

Chugh, Rashmi ;

Schuetze, Scott M. ;

Chamberlin, Mary D. ;

Haley, Barbara J. ;

Storniolo, Anna Maria, V ;

Reddy, Mridula P. ;

Anderson, Scott A. ;

Zimmerman, Collin T. ;

O'Dea, Anne P. ;

Mirshahidi, Hamid R. ;

Ahnert, Jordi Rodon ;

Brescia, Frank J. ;

Hahn, Olwen ;

Raymond, Jane M. ;

Biggs, David D. ;

Connolly, Roisin M. ;

Sharon, Elad ;

Korde, Larissa A. ;

Gray, Robert J. ;

Mayerson, Edward ;

Plets, Melissa ;

Blanke, Charles D. ;

Chae, Young Kwang ;

Kurzrock, Razelle .

CLINICAL CANCER RESEARCH, 2022, 28 (02) :271-278

[4] Dramatic response of metaplastic breast cancer to chemo-immunotherapy [J].

Adams, Sylvia .

NPJ BREAST CANCER, 2017, 3

[5] Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy [J].

Al-Hilli, Zahraa ;

Choong, Grace ;

Keeney, Michael G. ;

Visscher, Daniel W. ;

Ingle, James N. ;

Goetz, Matthew P. ;

Jakub, James W. .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) :709-716

[6]

[Anonymous], 2021, NCCN Clinical Practice Guidelines in Oncology Breast Cancer, V2021

[7] Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component [J].

Avigdor, Bracha Erlanger ;

Beierl, Katie ;

Gocke, Christopher D. ;

Zabransky, Daniel J. ;

Cravero, Karen ;

Kyker-Snowman, Kelly ;

Button, Berry ;

Chu, David ;

Croessmann, Sarah ;

Cochran, Rory L. ;

Connolly, Roisin M. ;

Park, Ben H. ;

Wheelan, Sarah J. ;

Cimino-Mathews, Ashley .

CLINICAL CANCER RESEARCH, 2017, 23 (16) :4875-4884

[8] Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab [J].

Basho, Reva K. ;

Gilcrease, Michael ;

Murthy, Rashmi K. ;

Helgason, Thorunn ;

Karp, Daniel D. ;

Meric-Bernstam, Funda ;

Hess, Kenneth R. ;

Herbrich, Shelley M. ;

Valero, Vicente ;

Albarracin, Constance ;

Litton, Jennifer K. ;

Chavez-MacGregor, Mariana ;

Ibrahim, Nuhad K. ;

Murray, James L., III ;

Koenig, Kimberly B. ;

Hong, David ;

Subbiah, Vivek ;

Kurzrock, Razelle ;

Janku, Filip ;

Moulder, Stacy L. .

JAMA ONCOLOGY, 2017, 3 (04) :509-515

[9] Metaplastic breast cancer: clinical significance [J].

Beatty, J. David ;

Atwood, Mary ;

Tickman, Ronald ;

Reiner, Maureen .

AMERICAN JOURNAL OF SURGERY, 2006, 191 (05) :657-664

[10]

Board WCoTE, 2019, MET CARC WHO CLASS T, V5th, P134

← 1 2 3 4 5 6 7 8 9 →